Classification of the incidence of adverse events (WHO):
very often> 1/10
often from> 1/100 to <1/10
infrequently from> 1/1000 to <1/100
rarely from> 1/10000 to <1/1000
very rarely from <1/10000, including individual messages.
From the cardiovascular system:
-often: marked decrease in blood pressure (in, at the beginning of therapy, with increasing dose or adherence to diuretic therapy), orthostatic hypotension, syncopal conditions;
-secondly: peripheral edema, palpitation, angina pectoris, arrhythmia;
-very rare: myocardial ischemia, myocardial infarction, increased circulatory disorders against the background of stenosing vascular lesions, Raynaud's syndrome, vasculitis, tachycardia, "tides" of blood to the skin of the face;
From the nervous system:
-frequently: headache, weakness;
-secondly: increased fatigue, nervousness, depression, tremor, imbalance, confusion, anxiety, dizziness, motor anxiety, sleep disorders;
-very rare: paresthesia, impaired perception of odors (parosmia), transient ischemic attacks, ischemic stroke, cerebral ischemia, impaired concentration;
From the genitourinary system:
- Transient impotence, decreased libido, impaired renal function up to acute renal failure, increased urine output, increased pre-existing proteinuria, increased urea and creatinine concentrations;
-very rare: gynecomastia;
From the respiratory system:
-frequently: "dry" non-productive cough, worse at night and in the "lying" position; more frequent in women and non-smoking patients, sinusitis, bronchitis, dyspnea;
- rarely: nasal congestion, pharyngitis, bronchospasm, including aggravation of the course of bronchial asthma;
From the skin:
-frequently: maculopapulletic skin rash;
- often: itchy skin, excessive sweating (against the background of a decrease in blood pressure);
-very rarely maculopapular rash and erythema, pemphigus, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, worsening of psoriasis flow psoriazoformnye, pemfigoidnye and lichenoid lesions of the skin and mucous membranes, alopecia;
-very rare: urticaria, onycholysis, exfoliative dermatitis, photosensitivity;
From the digestive system:
-Frequently: inflammation of the mucosa of the gastrointestinal tract, indigestion, abdominal discomfort, dyspepsia, nausea, diarrhea, vomiting;
-rare: increased activity "liver" enzyme, increasing the concentration of bilirubin, cholestatic jaundice, acute liver failure, cholestatic hepatitis, hepatocellular lesion, dryness of the oral mucosa, stomach pain, gastritis, constipation; pancreatitis, including with lethal outcome (pancreatitis cases fatal taking ACE inhibitors rarely observed), intestinal angioedema, decreased appetite, anorexia;
-very rare: glossitis; aphthous stomatitis;
From the musculoskeletal system:
-Often: myalgia, muscle cramps;
-only: arthralgia;
From the sense organs:
- Often: visual disorders, including blurred vision, conjunctivitis, hearing impairment, impaired sense of smell and taste (eg, metallic taste, partial or temporary loss of taste sensations);
Allergic reactions:
- Very rarely: angioedema with involvement of the mucous membrane of the lips, eyes, tongue, larynx and pharynx, anaphylactic or anaphylactoid reactions (poison of insects), an increase in the concentration of antinuclear bodies;
Laboratory indicators:
-secondly: hyperkalemia, moderate (sometimes pronounced) hypogemoglobinemia or neutropenia, erythropenia and thrombocytopenia, increased activity of pancreatic enzymes;
Very rarely: hyponatremia, proteinuria (although ACE inhibitors usually decrease previous proteinuria) or an increase in diuresis (in conjunction with worsening of the heart), agranulocytosis, pancytopenia, bone marrow depression, hemolytic anemia;
Other:
-perhaps: hyperthermia;
-very rare: fever.